ARV-based HIV prevention for women – where we are in 2014

Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioural, structural, cultural and social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of antiretroviral (ARV) drugs as pre-exposure...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastro, Timothy D, Sista, Nirupama, Abdool-Karim, Quarraisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Women and ARV-based prevention: opportunities and challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164013/
https://www.ncbi.nlm.nih.gov/pubmed/25224614
http://dx.doi.org/10.7448/IAS.17.3.19154
Descripción
Sumario:Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioural, structural, cultural and social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of antiretroviral (ARV) drugs as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition (sexually, parenterally and vertically) and ARV treatment (ART) for HIV-positive patients to prevent onward transmission (treatment as prevention – TasP). This paper reviews the evidence base for PrEP and TasP, describes new products in development and the need to translate research findings into programmes with impact at the population level.

Ejemplares similares